NAL3929

NAL3929 is a preclinical-stage injectable peptide being developed by NAL Pharmaceutical Group for the treatment of obesity and weight loss. It is a formulation of tirzepatide, a dual agonist of the glucagon-like peptide-1 (GLP-1) and gastric inhibitory polypeptide (GIP) receptors. By activating these receptors, NAL3929 mimics the action of endogenous incretin hormones to enhance glucose-dependent insulin secretion, suppress glucagon levels, and promote satiety, thereby facilitating weight reduction. The drug is designed for once-weekly subcutaneous administration and is currently listed in the developer's pipeline as a licensing opportunity for metabolic disease management.

Other names

NAL3929NAL-3929NAL 3929Tirzepatide 1-Week InjectionTirzepatide1-Week InjectionTirzepatide-1-Week Injectiontirzepatide